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Ab~ra~ 
Tumor necrosis factor-a (TNF-a) levels were measured in the plasma of patients with different ypes of Gaucher disease (GD) and 
patients with other lysosomal storage diseases. The highest TNF-a levels were observed in the most severe neuronopathic type of GD, 
exceeding those found in healthy individuals as well as patients with other lysosomal disorders. Type I GD cases showed a wide range of 
TNF-a levels ranging from normal to 2.5 × the highest control value. TNF-a is a pleiotropic ytokine produced mainly by activated 
macrophages. Our data suggest that it may play a role in the pathophysiology of GD disease. 
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1. Introduction 
Gaucher disease (GD) is a lipid storage disorder caused 
by the deficient activity of the lysosomal enzyme fl-gluco- 
cerebrosidase. This deficiency results in the impaired hy- 
drolysis of glucosylceramide (GC), a glycolipid that is 
preferentially cleared by macrophages of the monocyte- 
macrophage system. Lipid-laden macrophages are believed 
to be the cellular source of secondary abnormalities in 
Gaucher disease (GD) and are implicated in the pathogene- 
sis of the disorder [1]. Although in vitro studies have 
shown that glucosylceramide tr atment of monocytes stim- 
ulates interleukin-1 (IL-1) secretion data regarding cy- 
tokine levels in GD patients are scarce [2]. In the present 
study levels of TNF-a, a pleiotropic cytokine [3], were 
measured in the plasma of GD patients as well as patients 
with other lysosomal disorders. 
2. Patients and methods 
A total of 64 patients were examined. They included 30 
patients with Gaucher disease (25 type I, 4 type II and 1 
type III) and 34 patients with other lysosomal disorders 
namely metachromatic leukodystrophy (n = 5), Krabbe 
leukodystrophy (n = 5), GMl-gangliosidosis (n = 6), 
GMe-gangliosidosis (n = 3), mucopolypacharidosis III B 
(n = 7), mucolipidosis II, III (n = 4) and Niemann-Pick 
type C (n = 3). Eleven healthy individuals erved as con- 
trois. GD diagnosis was established by assaying /3-gluco- 
cerebrosidase in white blood cells and/or fibroblasts cul- 
tured from skin biopsies [4]. The diagnosis of the other 
lysosomal disorders was established by assaying the appro- 
priate lysosomal enzymes as previously described [5]. 
TNF-a was measured in plasma prepared from hep- 
arinised blood using the immunoenzymetric assay kit 
(TNF-a EASIA) by Medgenix (Belgium). The results were 
expressed in pg/ml.  
The investigation of GD patients also included the assay 
in plasma of /3-hexosaminidase, a-mannosidase [5] and 
chitotriosidase [6]. Severity score indexes were established 
according to Zimran [7]. 
3. Results 
* Corresponding author. Fax: + 30 1 7700111. 
The results obtained in our study with regard to TNF-a 
levels are shown in Fig. 1. On the whole the GD patients 
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Fig. 1. TNF-a levels in patients with Gaucher disease, cases type I, (GDI), type II, III (GDII, III), GM 1 and GM2-gangl iosidoses (GM 1, GM2),  
metachromatic leukodystrophy (MLD), Krabe leukodystrophy, mucopolysaccharidosis lII B (MPS III B) and mucolipidoses lI, III (MPL). 
showed higher TNF-a values than any of the groups 
examined, followed by Niemann-Pick C patients. The 
highest TNF-a plasma levels were found in neuronopathic 
GD cases exceeding by far those found in the control 
group as well as in patients with other lysosomal storage 
diseases. Furthermore with one exception there was a clear 
distinction between them and the type I cases. The latter 
showed a wide range of values ranging from normal to 
2.5 × the highest control value. 
In GD patients no correlation was found between TNF-a 
levels, residual white blood cell or fibroblast fl-gluco- 
cerebrosidase activity, plasma c~-mannosidase and chi- 
totriosidase activities. On the other hand a positive correla- 
tion that was statistically significant (P  < 0.05) was found 
between TNF-a and plasma /3-hexosaminidase activity. 
Severity scoring indexes (SSI) were available in 10 type 
I patients. In general patients with a higher SSI had a 
higher fl-hexosaminidase activity and a higher TNF-a 
Table 1 
Severity score indexes and plasma levels of  f l -hexosaminidase, TNF-a and chitotriosidase at different ime points of  ceredase treatment in Gaucher  disease 
type I cases. Control TNF-a values: 5 -31  pg /ml  
Patients Time SSI f l -Hexosaminidase TNF-a Chitotriosidase 
(mth) (nmol /ml  per h) (pg /ml )  (nmol /ml  per h) 
1 0 19 3127 70 12729 
3 - 2869 64 13929 
6 - 2528 82 6918 
12 - 2773 56 9412 
2 0 14 2607 35 15081 
3 - 2420 22 19200 
6 - 2233 18 17400 
12 - 1987 16 16769 
3 0 3 2155 23 - 
4 0 11 3715 77 39992 
3 - 2458 60 24631 
6 - 3008 82 - 
12 - 2266 52 27589 
5 0 14 2822 59 11180 
3 - 1979 50 8318 
7 - 2296 33 9670 
11.5 - 2109 50 
6 0 3 1107 15 - 
7 0 9 3101 23 - 
8 0 8 1138 23 - 
9 0 4 1701 21 - 
10 0 17 3265 23 22522 
0.5 - 3653 45 22913 
3 - 2608 38 14167 
6 - 1240 22 12845 
12 - 1113 8 
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value. However the relation was not always that clear e.g. 
patient 10 with a high SSI value had high /3-hexosamini- 
dase but low TNF-a levels whereas high TNF-a levels 
were observed in patient 4 who had a lower SSI value 
(Table 1). 
TNF-a was measured in 5 type I patients on Ceredase at 
different time points after the initiation of treatment. It was 
observed that similarly to chitotriosidase and fl-hexosa- 
minidase TNF-a tended to decrease over the period stud- 
ied. In fact 12 months after the initiation of Ceredase 
treatment all five patients had lower TNF-a levels than 
before therapy (Table 1). 
4. Discussion 
The impaired activity of the lysosomal enzyme fl-glu- 
cocerebrosidase in Gaucher disease prevents the catabolism 
of glucosylceramide (GC) that preferentially accumulates 
in macrophages. These lipid - -  laden cells accumulate 
mainly in spleen, liver and bone and are believed to be 
responsible for the pathologic processes characterising the 
disorder [ 1 ]. Altered monocyte-macrophage function due to 
the loading of the cells with undigested GC is suggested 
by the work of several authors [2,8-10]. Cytokines are 
emerging as molecules of key importance in homeostasis, 
development and pathophysiology. Alterations in their pro- 
duction and/or secretion may have important implications 
in the pathophysiology of GD. However although in vitro 
studies have shown that GC stimulated the secretion of 
interleukin-1 by macrophages [2], data concerning cytokine 
levels in GD patients are scarce [10]. TNF-a is a pleiotropic 
cytokine that has been implicated in several physiological 
and pathological processes [ 11-14]. Activated macrophages 
and T-lymphocytes are the principal source of the cytokine 
[3] that can nonetheless be produced by other cells such as 
astrocytes and microglia [15,16]. 
In our study increased TNF-a levels were observed in 
GD patients in a manner apparently related to the severity 
of the disorder, the highest levels being found in the most 
severe neuronopathic form of the disorder. TNF-a has been 
reported to change ionic channel expression and membrane 
potential of oligodendrocytes in vitro, to disrupt myelin, to 
cause necrosis of oligodendrocytes and to induce gliotic 
proliferation [17,18]. 
Plasma levels do not necessarily reflect he brain situa- 
tion, furthermore studies concerning the behaviour of 
TNF-a in the brain of GD patients are not available. 
However increased circulating levels of TNF-a could mod- 
ulate the transmigration of lymphocytes across cerebral 
endothelial cells [19] that could in turn secret cytokines in 
the brain as well as induce the secretion of TNF-a by 
microglia nd astrocytes [16,20]. 
Type I cases showed a wide range of TNF-a levels. The 
range of values is compatible both with the behaviour of 
other secondary serum abnormalities in Gaucher disease 
and the range of the clinical manifestations of the disorder 
[1]. 
The observed changes in the TNF-a levels during ther- 
apy and in particular in the patients howing high levels 
before its initiation further supports the concept of a causal 
relation between the disorder and cytokine secretion. 
In conclusion then our results show for the first time 
that TNF-a mainly produced by activated macrophages is 
elevated in the plasma of GD patients. The elevation is not 
paralled by any other lysosomal storage disorder. However 
before any definite conclusions are reached regarding the 
origin and mechanism of secretion of TNF-a as well as its 
implications in the pathology of the disorder more studies 
are required. 
Thus it will be important to evaluate TNF-a levels in 
large numbers of GD type I patients in relation ot only to 
SSI but also to individual manifestations e.g. bone involve- 
ment, since TNF-a and other cytokines have been impli- 
cated as potential inducers of osteoporosis [21,22] both 
before and during therapy. 
Furthermore analysis of several cytokines in plasma of 
GD patients, studies involving cytokine xpression i  vitro 
by peripheral monocytes of GD patients as well as in situ 
analysis of affected organs for expression of cytokines or 
cytokine mRNA, will be very important in understanding 
the basis of altered cytokine production and/or secretion 
and its contribution to the pathogenesis of Gaucher dis- 
ease. 
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